Ignite Creation Date:
2024-05-06 @ 5:08 PM
Last Modification Date:
2024-10-26 @ 2:22 PM
Study NCT ID:
NCT05206045
Status:
UNKNOWN
Last Update Posted:
2022-01-25
First Post:
2022-01-24
Brief Title:
Evolution of the SURvival of Patients With SEzary Syndrome SS Over the 1998-2020 Period and Its Association With the Early Use of Therapeutic Monoclonal Antibodies
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Assistance Publique - Hôpitaux de Paris
Study Overview
Official Title:
Evolution of the SURvival of Patients With SEzary Syndrome SS Over the 1998-2020 Period and Its Association With the Early Use of Therapeutic Monoclonal Antibodies
Status:
UNKNOWN
Status Verified Date:
2022-01
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SURPASSe
Brief Summary:
Sezary syndrome SS is a rare aggressive and advanced form of cutaneous T lymphoma with a poor prognosis 5-year survival rate varying between 24 and 52 The treatments are only suspensive with short-term remissions For the past fifteen years therapeutic approaches have been based on depleting monoclonal antibodies anti-CD52 anti-CCR4 anti-KIR3DL2 anti-CD70 or antibody-drug conjugates anti-CD30 But while the efficacy of mogamulizumab on progression-free survival was reported in the phase III study no study on a large cohort has compared the current overall survival of patients with Sezary syndrome to that before the era of monoclonal antibodies In this context we propose to report a large series of patients with Sézary syndrome in order to compare the current survival of patients with that of the pre-monoclonal antibodies era 1998-2003
The objective of this study is to assess the evolution of the overall survival of patients with Sezary syndrome since the early use of therapeutic monoclonal antibodies The underlying hypothesis of this study is that the use of therapeutic monoclonal antibodies has improved the prognosis of these patients Patients included in this retrospective study are patients with a Sezary syndrome diagnosed between 1998 and 2020
The objective of this study is to assess the evolution of the overall survival of patients with Sezary syndrome since the early use of therapeutic monoclonal antibodies The underlying hypothesis of this study is that the use of therapeutic monoclonal antibodies has improved the prognosis of these patients Patients included in this retrospective study are patients with a Sezary syndrome diagnosed between 1998 and 2020
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None